Poor
Mostly Aligned
Patient Risk:
Low
Summary
The AI response largely contains off-label or non-indication-related claims; only hypertension and tremor indications are represented as partially supported. A majority of statements pertain to shortages, regulatory actions outside the U.S., and dispensing protocols not described in the FDA label Indications and Usage.
Category Scores
Accurate Statements
Hypertension is an indication for propranolol.
INDICATIONS AND USAGE (Section 2)
Essential tremor is an indication for propranolol.
INDICATIONS AND USAGE (Section 2)
Unsupported Statements
Propranolol is a medication used to treat conditions such as high blood pressure, heart problems, anxiety, and tremors.
Anxiety is not an FDA-approved indication; only hypertension and tremor are clearly indicated in the label.
The United Kingdom has experienced shortages of propranolol.
FDA label Indications and Usage does not discuss country-specific shortages.
Propranolol shortages began in late 2022.
No information about supply timelines in FDA label.
Propranolol shortages persisted into 2023.
No information about supply timelines in FDA label.
Factors contributing to the shortage include increased global demand, manufacturing issues, and supply chain disruptions.
FDA label does not discuss shortages or manufacturing factors.
There is potential off-label use of propranolol for anxiety and other conditions.
Off-label use is not discussed in the FDA Indications and Usage section.
There was a surge in prescriptions for propranolol.
No information about prescription trends in the FDA label.
The Department of Health and Social Care (DHSC) issued Serious Shortage Protocols (SSPs) for propranolol.
DHSC SSPs are outside U.S. FDA label.
SSPs allow pharmacists to supply alternative strengths or different brands of propranolol without requiring a new prescription from a doctor, provided it is clinically appropriate.
No information about SSPs in FDA Indications and Usage.
SSPs are intended to ensure patients can continue to access the medication they need.
Not discussed in FDA Indications and Usage.
The DHSC has engaged with manufacturers to understand production volumes and delivery schedules.
Not present in FDA label.
Patients requiring propranolol have faced challenges in obtaining their prescribed medication.
Not discussed in FDA label.
A propranolol shortage can lead to treatment interruptions.
Not discussed in FDA label.
Treatment interruptions may cause underlying conditions to worsen.
Not discussed in FDA label.
SSPs provide flexibility in dispensing to mitigate risks.
Not discussed in FDA label.
Patients should consult with their pharmacist or doctor if they have concerns about their treatment.
Not discussed in FDA label.
Other beta-blockers are available for the conditions propranolol treats.
Not discussed in FDA label.
Other medications are available for the conditions propranolol treats.
Not discussed in FDA label.
Any change in medication needs to be carefully considered by a healthcare professional to ensure it is safe and effective for the individual patient.
Not discussed in FDA label.
The SSPs allow for switching between different propranolol formulations.
Not discussed in FDA label.
Contradictions
Important Omissions
No discussion of dosage, administration details, contraindications, warnings, adverse reactions, monitoring recommendations, or storage in the Indications and Usage context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Content relates to supply/regulatory issues; no direct patient safety risks described.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Content largely outside FDA labeling (shortages, SSPs, non-U.S. regulatory actions); only partial alignment on approved indications.
Suggested Improvement
Restrict content to FDA-approved Indications and Usage; avoid non-label topics (shortages, SSPs, UK DHSC actions) or clearly frame them as off-label/regulatory context.